Arvinas, Inc. (ARVN) is a breakthrough biopharmaceutical company pioneering the development of targeted therapies for serious diseases. Its unique approach revolutionizes traditional methods of cancer treatment by focusing on protein degradation. This method has the potential to provide treatments for diseases that have been resistant to various therapies.
Arvinas was founded by Craig Crews, a professor at Yale University, in 2013 and is headquartered in New Haven, Connecticut, United States. The company derives its name from the Latin phrase "arvina", which translates to "the grease of sheep's wool". This represents a dedication to creating transformative solutions in the medical field, much as the grease of sheep's wool was used historically in myriad unique applications.
Highlighted by its Proteolysis-Targeting Chimeras (PROTAC) technology, Arvinas stands out in the pharmaceutical world. PROTAC harnesses the body's own natural process of protein degradation to eliminate disease-causing proteins, enabling innovations in treatment across a multitude of serious diseases, including cancer and neurodegenerative disorders.
Arvinas' lead products, ARV-110 and ARV-471, are proprietary investigational medications administered orally which are being evaluated for safety, tolerability, and durability of anti-tumor responses to potential treatments in phases of clinical trials. ARV-110 is an androgen receptor PROTAC protein degrader, being studied in men with metastatic castrate-resistant prostate cancer. ARV-471 is an estrogen receptor PROTAC protein degrader, undergoing clinical trials for patients with locally advanced or metastatic ER+/HER2- breast cancer.
Arvinas has also been actively contributing to research in neurodegenerative diseases. As of now, it's working extensively on a potential treatment for Huntington's disease and is also engaged in the development of a new class of small molecule drugs known as protein homeostasis regulators to treat serious neurological conditions, such as amyotropic lateral sclerosis (ALS) and frontal temporal dementia (FTD).
The company’s work has attracted the attention of large pharmaceuticals. Its high-profile partnerships include collaborations with Pfizer and Genentech, boosting its financial stability and R&D capabilities.
Arvinas, Inc.'s main distinction lies in its dedication to revolutionizing the approach to serious illnesses by introducing revolutionary methods based on protein degradation.
Stock exchange-wise, ARVN is traded publicly on Nasdaq and has had a strong growth trajectory. While any biotech venture carries inherit risk, Arvinas, Inc. demonstrates a promising future with its powerful technology platform and strategic partnerships. Overall, the company portrays a solid commitment towards treating deadly diseases with its innovative science and strategic collaborations. As the company continues its research and moves closer to FDA approval for its therapies, it will certainly be one to watch.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Arvinas (NASDAQ:ARVN) shares rose 6.3% during midday trading on Wednesday, though trading volume was significantly below average. The company recently reported a strong quarterly beat with revenue up 1,014.7% year over year and EPS of $2.58. Analysts maintain a "Hold" rating with a consensus price target of $14.55.
Bank of America Corp DE has acquired 252,939 shares of Arvinas, Inc. (NASDAQ:ARVN), valued at approximately $2.1 million, representing 0.39% of the company. Institutional investors now own 95.19% of Arvinas. Analysts currently have a "Hold" rating on the stock with an average price target of $14.55, despite the company reporting strong quarterly revenue and earnings that significantly exceeded estimates.
Arvinas, Inc., a clinical-stage biotechnology company, announced the grant of an option to purchase 64,766 shares of common stock and 42,388 restricted stock units to a new employee. These awards were granted on September 28, 2026, under Nasdaq Listing Rule 5635(c)(4) and not through the company's stock incentive plan. The awards will vest over four years, subject to the employee's continued service.
Arvinas, Inc. has initiated a Phase I/II trial for ARV-6723, an oral PROTAC degrader targeting HPK1, marking its entry into immuno-oncology. This drug aims to degrade the HPK1 protein, a negative regulator of immune activation, and is being evaluated as both monotherapy and in combination with pembrolizumab for advanced solid tumors. ARV-6723 is the first HPK1 PROTAC degrader to enter clinical development in the US, expanding Arvinas's PROTAC pipeline.
Arvinas Inc. reported significant progress in Q2 2026, including the FDA approval of its PROTAC degrader Vepanu, an out-licensing agreement with Rigel Pharmaceuticals, and a strategic decision to seek a partner for its KRAS G12D program. The company is now focusing on advancing its Phase 1 clinical programs for ARV393 (BCL6 degradation), ARV027 (polyglutamine repeat androgen receptors), and ARV102 (LRRK2 degradation). Arvinas ended the quarter with $567.9 million in cash, reported $249.7 million in total revenue, and expects its cash runway to last into the second half of 2028.